Welcome to our dedicated page for Apellis Pharmace news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmace stock.
Apellis Pharmaceuticals, Inc. reports news on its commercial-stage biopharmaceutical business centered on complement science and C3-targeting medicines. Recurring updates cover SYFOVRE, a pegcetacoplan injection for geographic atrophy secondary to age-related macular degeneration, and EMPAVELI, pegcetacoplan for rare diseases including paroxysmal nocturnal hemoglobinuria and rare kidney indications.
Company news also includes product revenue updates, ophthalmology and nephrology data presentations, pipeline references tied to complement biology, board and governance changes, investor conference participation, collaboration matters, and corporate-status developments involving strategic transactions and related shareholder communications.
Apellis Pharmaceuticals (Nasdaq: APLS) announced an updated timing for its fireside chat at the Bank of America Global Healthcare Conference. The chat is scheduled for September 16, 2022, at 9:55 a.m. BST / 4:55 a.m. ET. This event will be accessible via a live webcast on the company's website. Apellis is recognized for its innovative work in complement medicine, having introduced the first targeted C3 therapy in 15 years to treat rare, retinal, and neurological diseases.
Apellis Pharmaceuticals announced the approval of equity awards for 64 new employees on September 1, 2022. The awards consist of options for 12,500 shares and 113,372 restricted stock units (RSUs). The options have an exercise price of $63.58, the closing price on the grant date. Vesting for the options occurs over four years, while RSUs vest at 25% annually. These grants are part of Apellis' 2022 Inducement Stock Incentive Plan and are crucial for employee retention. This announcement signifies Apellis' commitment to recruiting top talent in the biopharmaceutical sector.
Apellis Pharmaceuticals (Nasdaq: APLS) will participate in several investor conferences in September 2022. Notable events include the Citi 17th Annual BioPharma Conference on September 7 at 1:00 p.m. ET, the Wells Fargo Healthcare Conference on September 8 at 1:55 p.m. ET, the Baird 2022 Global Healthcare Conference on September 14 at 3:10 p.m. ET, and the BofA Global Research Healthcare Conference on September 16 at 10:05 a.m. ET. Webcasts will be available on their website for 30 days post-event.
Apellis Pharmaceuticals announced positive 24-month data from Phase 3 DERBY and OAKS studies on pegcetacoplan for geographic atrophy (GA) linked to age-related macular degeneration (AMD). Treatment effects accelerated between months 18-24, with notable reductions in GA lesion growth: DERBY showed 36% (monthly) and 29% (every-other-month), while OAKS reported 24% (monthly) and 25% (EOM) reductions. The drug maintained a favorable safety profile, with no significant adverse events. A potential first approval in the U.S. is expected by Nov. 26, 2022, with European submission planned by year-end.
Apellis Pharmaceuticals (APLS) announced significant updates in its Q2 2022 report, achieving $15.7 million in U.S. net revenue from EMPAVELI. The company received FDA acceptance for a New Drug Application for pegcetacoplan targeting geographic atrophy, with a review target date of November 26, 2022. Cash and investments totaled $852.8 million as of June 30, 2022, ensuring a runway into Q1 2024. Notably, Apellis also initiated a Phase 3 study for IC-MPGN and C3G, marking a transformative period for the company, as it advances multiple therapeutic programs.
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced the grant of equity awards to two new employees as of August 1, 2022. These equity inducement awards are outside of the company's 2017 Stock Incentive Plan, aligning with the terms of the 2022 Inducement Stock Incentive Plan. Each employee received options for 2,409 restricted stock units (RSUs), which will vest at 25% annually over four years, contingent upon continued employment. This initiative is part of Apellis' strategy to attract top talent in the biopharmaceutical sector.
Apellis Pharmaceuticals (Nasdaq: APLS) announced a conference call on August 8, 2022, at 4:30 p.m. ET to discuss its second quarter 2022 financial results. Investors can pre-register for the live call and access a webcast with accompanying slides on the company's website. Apellis is recognized for its leadership in complement therapeutics, having introduced the first new class of complement medicine in 15 years. The company aims to develop transformative therapies for rare, retinal, and neurological diseases.
Apellis Pharmaceuticals, Inc. (Nasdaq:APLS) announced on July 27, 2022, the completion of privately negotiated exchange agreements involving its 3.500% Convertible Senior Notes due 2026. Approximately $65.9 million of these Notes will be exchanged for 2,036,886 shares of common stock, while another $9.7 million will be swapped for additional shares based on a calculated valuation. The transactions are set to close by August 1, 2022, contingent on customary conditions. Notably, the shares issued will not be registered under the Securities Act, limiting their sale.
Apellis Pharmaceuticals (Nasdaq: APLS) announced that the FDA has accepted its New Drug Application (NDA) for pegcetacoplan, a targeted C3 therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). The PDUFA target action date is set for November 26, 2022. This application has been granted a Priority Review designation, highlighting its potential as a breakthrough treatment. The submission is based on data from the Phase 2 FILLY and Phase 3 DERBY and OAKS studies, involving over 1,500 patients, showing clinically meaningful results and a favorable safety profile.
Apellis Pharmaceuticals (Nasdaq: APLS) announced significant new data from Phase 3 studies at the American Society of Retina Specialists Annual Meeting. The results support the efficacy of pegcetacoplan in slowing lesion growth in geographic atrophy (GA) associated with age-related macular degeneration (AMD). The company submitted a New Drug Application to the FDA in June 2022, with a decision on acceptance expected in August 2022. Pegcetacoplan has no current approved treatments for GA, highlighting an urgent need for effective therapies for this debilitating condition.